352287-39-9

Upstream product

• 352288-44-9 (E)-3-[1,1';3',1]terphenyl-5'-yl-prop-2-en-1-ol 
• 222555-06-8 ethyl (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate 
• 220955-80-6 [1,1′:3′,1″-terphenyl]-5′-carbaldehyde 
• 352288-43-8 (E)-ethyl 3-[1,1';3',1]terphenyl-5'-yl-acrylate 
• 56990-02-4 3,5-dibromobenzaldehyde 
• 98-80-6 phenylboronic acid 
• 197299-16-4 ethyl 2-ethoxy-3-(4-hydroxy-phenyl)-propionate 

Relevant academic research and scientific papers

Design of potent PPARα agonists

Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPARα agonists. Optimum PPARα potency and selectivity were obtained with substituents having van der Waals volume around 260. Compound 6 had a PPARα potency of 0.002 μM and a selectivity ratio to PPARγ and PPARδ of 410 and 2000, respectively.

Compounds, their preparation and use

The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).